Goldman Sachs Group Inc Voyager Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $706 Billion
  • Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 280,916 shares of VYGR stock, worth $1.52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
280,916
Previous 223,375 25.76%
Holding current value
$1.52 Million
Previous $755,000 15.63%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$2.73 - $3.64 $157,086 - $209,449
57,541 Added 25.76%
280,916 $873,000
Q1 2025

May 09, 2025
SELL
$3.38 - $6.04 $229,424 - $409,977
-67,877 Reduced 23.31%
223,375 $755,000
Q4 2024

Feb 11, 2025
SELL
$5.27 - $8.07 $195,379 - $299,187
-37,074 Reduced 11.29%
291,252 $1.65 Million
Q3 2024

Nov 14, 2024
SELL
$5.77 - $9.27 $667,346 - $1.07 Million
-115,658 Reduced 26.05%
328,326 $1.92 Million
Q2 2024

Aug 13, 2024
BUY
$7.42 - $10.54 $462,080 - $656,378
62,275 Added 16.31%
443,984 $3.51 Million
Q1 2024

May 15, 2024
BUY
$7.15 - $10.84 $1.44 Million - $2.19 Million
201,684 Added 112.03%
381,709 $3.55 Million
Q4 2023

Feb 13, 2024
BUY
$6.28 - $8.81 $244,329 - $342,761
38,906 Added 27.57%
180,025 $1.52 Million
Q3 2023

May 14, 2024
SELL
$7.55 - $11.25 $293,740 - $437,692
-38,906 Reduced 21.61%
141,119 $1.09 Million
Q3 2023

Nov 14, 2023
BUY
$7.55 - $11.25 $443,185 - $660,375
58,700 Added 71.22%
141,119 $1.09 Million
Q2 2023

May 14, 2024
SELL
$6.94 - $13.99 $636,335 - $1.28 Million
-91,691 Reduced 52.66%
82,419 $943,000
Q2 2023

Aug 14, 2023
SELL
$6.94 - $13.99 $636,335 - $1.28 Million
-91,691 Reduced 52.66%
82,419 $943,000
Q1 2023

May 14, 2024
BUY
$6.0 - $10.78 $626,184 - $1.13 Million
104,364 Added 149.63%
174,110 $1.34 Million
Q1 2023

May 11, 2023
BUY
$6.0 - $10.78 $626,184 - $1.13 Million
104,364 Added 149.63%
174,110 $1.34 Million
Q4 2022

May 14, 2024
SELL
$4.94 - $6.61 $82,043 - $109,778
-16,608 Reduced 19.23%
69,746 $425,000
Q4 2022

Feb 13, 2023
SELL
$4.94 - $6.61 $82,043 - $109,778
-16,608 Reduced 19.23%
69,746 $425,000
Q3 2022

May 14, 2024
SELL
$5.57 - $7.47 $130,822 - $175,447
-23,487 Reduced 21.38%
86,354 $512,000
Q3 2022

Nov 10, 2022
SELL
$5.57 - $7.47 $130,822 - $175,447
-23,487 Reduced 21.38%
86,354 $511,000
Q2 2022

May 14, 2024
SELL
$4.82 - $10.09 $338,286 - $708,156
-70,184 Reduced 38.99%
109,841 $649,000
Q2 2022

Aug 15, 2022
SELL
$4.82 - $10.09 $17,925 - $37,524
-3,719 Reduced 3.27%
109,841 $649,000
Q1 2022

May 16, 2022
BUY
$2.75 - $9.44 $220,761 - $757,814
80,277 Added 241.2%
113,560 $865,000
Q4 2021

Feb 14, 2022
SELL
$2.47 - $5.55 $55,980 - $125,785
-22,664 Reduced 40.51%
33,283 $90,000
Q3 2021

Nov 10, 2021
BUY
$2.63 - $4.12 $147,140 - $230,501
55,947 New
55,947 $147,000

Others Institutions Holding VYGR

# of Institutions
120
Shares Held
32.8M
Call Options Held
32.9K
Put Options Held
22.7K
View Full List

About Voyager Therapeutics, Inc.

VYGR Quotes by TradingView
  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $209M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email